Showing 3661-3670 of 4764 results for "".
- SkylineDx and Mayo Clinic To Collaborate on Development of Diagnostic Tests for Melanomahttps://practicaldermatology.com/news/skylinedx-and-mayo-clinic-to-collaborate-on-development-of-diagnostic-tests-for-melanoma/2457903/SkylineDx and Mayo Clinic are working together to develop novel diagnostic tests which will improve clinical decision making for melanoma patients. SkylineDx will help Mayo Clinic to optimize and further develop an algorithm to identify risk factor
- Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in EBhttps://practicaldermatology.com/news/abeona-receives-fda-regenerative-medicine-advanced-therapy-designation-for-eb-101-gene-therapy-in-eb/2457908/The US Food and Drug Administration (FDA) granted the Regenerative Medicine Advanced Therapy (RMAT) designation to EB-101, Abeona Therapeutics Inc.’s gene-corrected autologous cell therapy product for patients with recessive dystrophic epidermolysis bullosa (RDEB). “EB-101 is
- Anti-IL22 Therapy May Represent New Treatment Option for Severe ADhttps://practicaldermatology.com/news/researchers-close-in-on-possible-new-treatment-for-severe-ad/2457913/New research suggests that IL-22/Th22 targeting may offer a novel treatment alternative for patients with severe atopic dermatitis (AD). The findings, which appear in the Journal of the American Academy of Dermatology, provide the first e
- New from Nerium: Prolistic Probiotic Productshttps://practicaldermatology.com/news/new-from-nerium-prolistic-probiotic-products/2457921/Nerium International is rolling out Prolistic™ Pre & Probiotic Plus Vitamins powder packets and Prolistic™Skin-Balancing Lotion with Probiotic Technology. The new Prolistic Pre & Probiotic Plus Vitamins powder
- Cochrane Review: Biologics Trump Other Systemics for Psohttps://practicaldermatology.com/news/cochrane-review-biologics-trump-other-systemic-meds-for-pso/2457924/Biologics appear to be the most effective systemic medicines for achieving a chronic plaque psoriasis score of PASI (Psoriasis Area and Severity Index) 90, according to a newly published Cochrane Revie
- Desmoplastic Melanoma May Be Highly Responsive to Anti-PD-1/PD-L1 Therapieshttps://practicaldermatology.com/news/desmoplastic-melanoma-may-be-highly-responsive-to-anti-pd-1pd-l1-therapies/2457926/Patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed, Moffitt Cancer Center researchers report in the Jan. 10 issue of Nature. Pembrolizumab and niv
- New Ceramide-Infused Skin Barrier Product Reduces Costs for Ostomy Carehttps://practicaldermatology.com/news/new-ceramide-infused-skin-barrier-product-reduces-costs-for-ostomy-care/2457929/Ostomy patients using a new type of skin barrier product infused with ceramides may experience lower costs of care, according to a randomized trial published
- FDA Grants AbbVie's Upadacitinib Breakthrough Therapy Designation for Atopic Dermatitishttps://practicaldermatology.com/news/fda-grants-abbvies-upadacitinib-breakthrough-therapy-designation-for-atopic-dermatitis/2457932/The FDA granted Breakthrough Therapy Designation for AbbVie's investigational, once-daily oral JAK1-selective inhibitor upadacitinib (ABT-494) in adult patients with moderate to severe atopic dermatitis who are candidates for systemic therapy. This Breakthrough Therapy Designation is supporte
- BioPhotas, Inc. Launches the Newest Model of the Celluma Serieshttps://practicaldermatology.com/news/biophotas-inc-launches-the-newest-model-of-the-celluma-series/2457943/BioPhotas, Inc. launched its Celluma HOME, a fourth model in the Celluma Series of light therapy devices. The company says the Celluma HOME specifically addresses the challenges of Baby Boomers who struggle with wrinkles, aches and pain. FDA-cleared for over-the-counter purchase, available at an
- Med Spas on Fleek with Millennialshttps://practicaldermatology.com/news/med-spas-on-fleek-with-millennials/2457940/Younger generations are driving the med spa boom, according to a new American Med Spa Association (AmSpa) study. The medical spa industry is one of the fastest developing in the US, with revenues growing at a double-digit pace since 2010, and by more than 20 percent each year since 2013.